Cardiotoxicity

The damage can be temporary or lasting. Some substances disrupt cardiac rhythm transiently — the effect clears when the drug does, and the heart returns to normal function. Others cause progressive structural change to the heart muscle itself, reducing its pumping efficiency, sometimes in ways that continue long after use stops.

Two mechanisms account for most of this harm. Direct myocardial toxicity damages muscle cells, impairing contractile function. Conduction toxicity disturbs the ion channels that time each beat — the electrical sequence that keeps contractions regular — creating conditions for arrhythmia: an irregular rhythm that can be benign or, in some circumstances, immediately dangerous.

Many substance classes carry some evidence of cardiac liability: stimulants by placing sustained demands on an elevated heart rate, inhalants by sensitising the heart to arrhythmia, and chronic heavy alcohol use by progressively weakening the heart wall.

How it is done

Cardiotoxicity risk is characterised through several layers of evidence. The earliest and most common is in vitro ion channel screening — particularly whether a compound blocks the hERG channel, a cardiac potassium channel whose blockade can prolong the electrical interval between beats, a condition linked to potentially dangerous arrhythmia.

Animal studies extend that signal to a living system, testing whether the compound causes measurable conduction changes or structural damage. Human evidence accumulates through QT interval monitoring in clinical settings, cardiovascular event rates in population data, and case reports of cardiac incidents in recreational contexts.

In harm-reduction practice, the relevant step is knowing which conditions amplify a substance's cardiac liability: pre-existing heart conditions, concurrent stimulant use, elevated body temperature, physical exertion, and electrolyte depletion. Chest pain, palpitations, or sudden breathlessness during use are the warning signs that warrant stopping.

When it matters

Cardiotoxicity becomes an emergency when cardiac symptoms appear during or shortly after substance use: chest pain, an irregular or racing heartbeat, sudden breathlessness, or loss of consciousness. These can represent acute arrhythmia or cardiac injury, both of which can deteriorate quickly.

At that point, accurate information about what was taken — the substances involved and the approximate time of use — is the most useful thing bystanders can provide to emergency responders.

What it cannot tell you

The most important limit is the gap between mechanistic evidence and real-world incidence. A substance that blocks a cardiac ion channel in a laboratory has a demonstrated mechanism of harm — but this does not establish that harm occurs at the concentrations reached during typical use, or in people without pre-existing risk factors.

The reverse gap matters equally: the absence of documented cardiac events does not mean safety. Rare or delayed events require large surveillance populations to detect. Many recreational substances have never been studied at that scale.

Individual susceptibility adds further uncertainty. Genetic variation in cardiac ion channel function, undiagnosed structural abnormalities, and the specific combination of substances and circumstances present all influence whether a laboratory mechanism ever becomes a clinical event for any given person. The evidence characterises the hazard; it cannot specify who encounters it.